Related Experiment Video
Updated: Jun 24, 2026

Employing the Forced Oscillation Technique for the Assessment of Respiratory Mechanics in Adults
Published on: February 9, 2022
Elevated exhaled nitric oxide (NO) in asymptomatic asthmatics taking bronchodilators on demand with controlled body
1Department of Physiology, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia.
Objective:
Fractional Exhaled Nitric Oxide (FENO) is a recently introduced non invasive marker to measure inflammation and oxidative stress in the lung. This study aimed to measure FENO in Saudi asthmatic adult patients who had mild to moderate persistent asthma, on inhaled short-acting? 2 agonists and compared them to healthy individuals matched for body composition without any evidence of obstructive airway disease.
Methods:
As per selection criteria 61 subjects were selected. 30 subjects were known asthmatic and 31 were healthy individuals matched for age, height, weight, BMI and body composition. Forced expiratory volume in 1 s (FEV1), FVC, FEV1/ FVC, PEF, FEF25, FEF50 and FEF75 were measured by standard methods. FENO measurements were performed according to the ATS (American Thoracic Society) recommendations.
Results:
Ventillatory function parameters FEV1 (p = 0.0020), FVC (p = 0.0030), PEF (p = 0.0121), FEF25 (p = 0.0241), FEF50 (p = 0.0240) and FEF75 (p = 0.1824) were significantly lower in asthmatic subjects compared to matched healthy control group. FENO was significantly higher (82.51 +/- 39.26) in asthmatic subjects compared to control group (23.03 +/- 8.56) p < 0.0000)
Conclusion:
FENO levels are increased in patients with bronchial asthma with mild to moderate symptoms taking bronchodilators on demand only. It may be suggestive of the need for more accurate evaluation and early intervention with anti inflammatory drugs in a significant proportion of these patients.
Related Concept Videos
COPD: Management Using Bronchodilators and Corticosteroids
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Asthma III: Clinical Manifestations
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Asthma-III: Symptoms and Complications
Classification of Asthma
